<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00218465</url>
  </required_header>
  <id_info>
    <org_study_id>NIDA-19378-2</org_study_id>
    <secondary_id>U01DA019378</secondary_id>
    <secondary_id>IND 74964</secondary_id>
    <nct_id>NCT00218465</nct_id>
  </id_info>
  <brief_title>Effectiveness of GW468816, an NMDA Glycine Site Antagonist, for Prevention of Relapse to Smoking</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled Trial of the NMDA Glycine Site Antagonist, GW468816, for Prevention of Relapse to Smoking</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mclean Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of the glycine antagonist, GW468816,
      compared with placebo on duration of abstinence and rates of relapse in recently quit female
      smokers in a randomized, double-blind, five-week clinical trial.

      According to the investigators, the new medication, GW468816, is thought to send certain
      signals in the brain that may be effective in helping people stay abstinent after they have
      recently quit smoking. GW468816 is a non-nicotine drug.

      The investigators of this study hypothesize that subjects receiving GW468816 will demonstrate
      a significantly longer time to relapse to smoking than those in the placebo group, as
      measured by the primary outcome measure (see below).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Smoking is the leading cause of preventable mortality in developed countries.
      Pharmacotherapy, including bupropion and nicotine replacement therapy (NRT), is universally
      recommended for smoking cessation treatment; however, even with treatment, the majority of
      smokers either fail to quit in the short term or relapse in the first year. The high failure
      rate reported for smoking cessation, then, presents a challenge to explore innovative
      approaches to treating relapse to smoking.

      The purpose of this study, then, is to evaluate the efficacy of the glycine antagonist,
      GW468816, compared with placebo on duration of abstinence and rates of relapse in female
      outpatient smokers during a randomized, double-blind, five-week clinical trial.

      To do this, the investigators will conduct a two-phase study, in which 300 adult, female
      outpatient smokers will be enrolled.

      Phase I will consist of an 8-week smoking cessation study in which nicotine replacement
      therapy (NRT) and a behavioral intervention are openly administered on a tapered schedule.
      Participants who are able to quit smoking after 7 weeks in this preliminary study will then
      be eligible to enter Phase II.

      Phase II is a 5-week, double-blind, placebo-controlled, relapse prevention trial with the
      investigational medication, GW468816.

      Participants in the Phase I smoking cessation study will begin by receiving nicotine
      replacement therapy in the form of the patch and brief support to stop smoking. Participants
      will be required to schedule office visits every 1-2 weeks throughout Phase I.

      Subjects who are abstinent at the end of Phase I will be eligible to continue Phase II, in
      which they will be randomly assigned by chance to receive the investigational medication,
      GW468816, at 200 mg or placebo (a pill that looks exactly like the study drug but contains no
      active drug). Participants will be required to schedule weekly office visits throughout Phase
      II.

      Subjects who complete the 15-week trial (both Phases I and II) will enter the 6-Month
      Follow-Up to evaluate rates of long term abstinence from nicotine. They will have office
      visits at Weeks 20, 24, 28, 32, 36, and 40 after discontinuation of study medications.

      Participants who enter the study will be offered the opportunity to participate in an
      ancillary neuroimaging study of mechanisms and surrogate markers of relapse that includes
      BOLD fMRI and MR spectroscopy, to be carried out at the McLean Brain Imaging Center.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Relapse to Smoking in the 5-week Relapse Prevention Phase.</measure>
    <time_frame>5 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Abstinent and Nonabstinent Participants at End of 5 Week Placebo-controlled Relapse Prevention Trial</measure>
    <time_frame>5 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Days to Relapse Within the 60 Days Following Randomization</measure>
    <time_frame>60 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">264</enrollment>
  <condition>Nicotine Dependence</condition>
  <arm_group>
    <arm_group_label>GW468816</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glycine Antagonist GW468816, 200 mg/day, for a 5-week trial</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, 200 mg/day, for a 5-week trial</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GW468816</intervention_name>
    <description>Pharmacotherapies for Relapse Prevention</description>
    <arm_group_label>GW468816</arm_group_label>
    <other_name>GW468816: NMDA glycine-site antagonist</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Comparator: Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent

          2. WOMEN aged 18-65 years, inclusive

          3. Self-report of smoking 10 or more cigarettes per day in the past 6 months and expired
             air CO &gt;10 ppm at the time of enrollment

          4. DSM-IV criteria for current Nicotine Dependence satisfied

          5. Subjects must be willing to take the study medication and be motivated to quit smoking
             (willing to set a quit date within 2 weeks of entry into the protocol)

          6. Women of childbearing potential must have a negative urine pregnancy test
             (quantitative HCG) at baseline and at week 8, prior to receiving the first dose of
             study medication and females must agree to use an approved form of contraception from
             the day of the first dose of study medication for 90 days after the last dose of study
             medication. Approved forms of contraception include any of the following:

               -  Complete abstinence from intercourse from 2 weeks prior to administration of the
                  study drug, through the treatment phase and for 90 days after discontinuation of
                  study medication.

               -  Sterilization of male partner

               -  Implant of levonorgestrel

               -  Injectable progesterone

               -  Intrauterine device (IUD) with &lt;1 percent rate of failure per year

               -  Any other method with published rate of failure of &lt;1 percent per year Due to
                  induction of cytochrome p450 3A4, oral contraceptives may be continued during the
                  study but cannot be relied upon as a sole means of contraception, and a second
                  method of contraception such as a barrier method will be required and reimbursed
                  by the study.

        Exclusion Criteria:

          1. Pregnant or able to become pregnant and not willing to use approved contraception

          2. Severe unstable medical illness including cardiovascular, hepatic, renal, respiratory,
             metabolic, neurological, or hematological disease by history, physical examination or
             clinical laboratory test results such that hospitalization for treatment of that
             illness is likely within the next two months

          3. Life-threatening arrhythmia, cerebro-vascular or cardiovascular event within six
             months of enrollment

          4. Elevation over 1.5 times upper limit of normal value (ULN) of any of the following
             laboratory results: Total, conjugated, or unconjugated bilirubin; alkaline
             phosphatase, alanine transferase (ALT), aspartate aminotransferase (AST), creatine
             phosphokinase (CPK), or lactate dehydrogenase (LDH).

          5. Use of tobacco-containing products other than cigarettes (e.g., cigar, pipe)

          6. Abuse or dependence of any substance other than nicotine or caffeine in the past 6
             months. Abuse of alcohol is here defined as an average weekly intake of greater than
             21 units or an average daily intake of greater than three units (males) or defined as
             an average weekly intake of greater than 14 units or an average daily intake of
             greater than two units (females). One unit is equivalent to a half-pint (220mL) of
             beer or one (25mL) measure of spirits or one glass (125mL) of wine.

          7. Diagnosis of major depressive disorder in the past 6 months

          8. Lifetime DSM-IV diagnosis of organic mental disorder, schizophrenia, schizoaffective
             disorder, bipolar disorder, delusional disorder or psychotic disorders not elsewhere
             classified

          9. History of non-response in the past month to an adequate trial of nicotine re
             placement therapy, defined as nicotine replacement &gt; 21 mg per day patch (or
             equivalent dose of gum, inhaler, nasal spray, or lozenge) for at least 4 weeks.

         10. History of multiple adverse drug reactions

         11. Use of an investigational drug or device within 4 weeks of enrollment

         12. Concurrently enrolled in a study that involves exposure to a drug or device.

         13. Urine positive for drugs of abuse at screening visit.

         14. Use of statins during the period of the investigation.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maurizio Fava, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eden Evins, M.D., M.P.H.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>McLean Hospital, Brain Imaging Center</name>
      <address>
        <city>Belmont</city>
        <state>Massachusetts</state>
        <zip>02478 9106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2005</study_first_submitted>
  <study_first_submitted_qc>September 16, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <results_first_submitted>August 2, 2010</results_first_submitted>
  <results_first_submitted_qc>November 23, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 20, 2010</results_first_posted>
  <last_update_submitted>March 22, 2017</last_update_submitted>
  <last_update_submitted_qc>March 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Maurizio Fava, MD</investigator_full_name>
    <investigator_title>Maurizio Fava, M.D.</investigator_title>
  </responsible_party>
  <keyword>Drugs, Investigational</keyword>
  <keyword>Therapies for Relapse to Nicotine</keyword>
  <keyword>Relapse Prevention</keyword>
  <keyword>Nicotine Cessation Therapies</keyword>
  <keyword>Smoking Cessation</keyword>
  <keyword>Nicotine Dependence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
    <mesh_term>Glycine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>816 Group</title>
          <description>Glycine Antagonist GW468816, 200 mg/day, for a 5-week trial.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo group for 5 week relapse prevention trial.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>816 Group</title>
          <description>Glycine Antagonist GW468816, 200 mg/day, for a 5-week trial.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo group for 5 week relapse prevention trial.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
            <count group_id="B2" value="48"/>
            <count group_id="B3" value="98"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="98"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.3" spread="10.5"/>
                    <measurement group_id="B2" value="46.5" spread="10.4"/>
                    <measurement group_id="B3" value="47.9" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="98"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Relapse to Smoking in the 5-week Relapse Prevention Phase.</title>
        <time_frame>5 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>816 Group</title>
            <description>Glycine Antagonist GW468816, 200 mg/day, for a 5-week trial.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo group for 5 week relapse prevention trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Relapse to Smoking in the 5-week Relapse Prevention Phase.</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5" spread="14.0"/>
                    <measurement group_id="O2" value="12.4" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Abstinent and Nonabstinent Participants at End of 5 Week Placebo-controlled Relapse Prevention Trial</title>
        <time_frame>5 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>816 Group</title>
            <description>Glycine Antagonist GW468816, 200 mg/day, for a 5-week trial.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo group for 5 week relapse prevention trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Abstinent and Nonabstinent Participants at End of 5 Week Placebo-controlled Relapse Prevention Trial</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Days to Relapse Within the 60 Days Following Randomization</title>
        <time_frame>60 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>816 Group</title>
            <description>Glycine Antagonist GW468816, 200 mg/day, for a 5-week trial.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo group for 5 week relapse prevention trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Days to Relapse Within the 60 Days Following Randomization</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.8" spread="18.3"/>
                    <measurement group_id="O2" value="20.6" spread="20.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Five weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>816 Group</title>
          <description>Glycine Antagonist GW468816, 200 mg/day, for a 5-week trial.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo group for 5 week relapse prevention trial.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>small cell adenocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>facial edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiovascular</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="50"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General/Administration Site</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="50"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous System</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="50"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatological</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sara Carlini</name_or_title>
      <organization>Center for Addiction Medicine</organization>
      <phone>617-643-1990</phone>
      <email>scarlini@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

